Table 2.

Clinical hazard mediation by platelet activity in subjects with CKD

Platelet variable adjustment		Outcome
		MI	Death	MACE	MACLE
Unadjusted model	HR [95% CI]	2.38 [1.09, 5.20]	2.31 [1.29, 4.12]	2.32 [1.40, 3.84]	1.56 [1.11, 2.19]
ADP 0.4 μM	aHR [95% CI]	2.15 [0.98, 4.73]	2.18 [1.22, 3.91]	2.22 [1.34, 3.69]	1.46 [1.03, 2.06]
	% mediation [95% CI]	17% [−25 −85%]	10% [−15 −61%]	7% [−11 −29%]	18% [−32 −113%]
Serotonin 10 μM	aHR [95% CI]	2.17 [0.99, 4.76]	2.21 [1.23, 3.96]	2.22 [1.34, 3.68]	1.42 [1.00, 2.00]
	% mediation [95% CI]	16% [−33 −101%]	8% [−16 −41%]	8% [−6 −33%]	26% [−20 −150%]
Epinephrine 2 μM	aHR [95% CI]	2.28 [1.04, 4.98]	2.17 [1.21, 3.88]	2.23 [1.35, 3.69]	1.45 [1.03, 2.05]
	% mediation [95% CI]	8% [−24 −36%]	11% [−12 −42%]	7% [−7 −25%]	18% [−22 −102%]
AA 1600 μM + ASAev	aHR [95% CI]	2.24 [1.02, 4.93]	2.19 [1.22, 3.94]	2.20 [1.32, 3.67]	1.47 [1.04, 2.08]
	% mediation [95% CI]	11% [−50 −47%]	9% [−22 −41%]	9% [−11 −29%]	16% [−24 −79%]
All 4 variables	aHR [95% CI]	2.19 [0.99, 4.86]	2.16 [1.20, 3.89]	2.21 [1.33, 3.68]	1.41 [1.00, 2.00]
	% mediation [95% CI]	14% [−81 −104%]	11% [−36 −56%]	9% [−22 −40%]	26% [−88 −152%]

AA, arachidonic acid; ADP, adenosine diphosphate; aHR, adjusted hazard ratio; ASAev, ex vivo aspirin; CI, confidence interval; HR, hazard ratio; MI, myocardial infarction; MACE, major adverse cardiovascular event; MACLE, major adverse cardiovascular and limb event.